快速免疫斑点法检测AQP4抗体用于视神经脊髓炎谱系疾病
这项多中心病例对照研究(2020年5月至2023年2月,4个医学中心)验证了酶免疫斑点法检测AQP4-IgG的性能。在200例AQP4-IgG阳性NMOSD患者和200例健康对照中,免疫斑点法与金标准CBA的一致性κ=98.0%。验证集中436例仅2例(<1%)假阳性、无假阴性;总体灵敏度99.4%(95%CI 97.8%-99.9%),特异度99.2%(95%CI 98.0%-99.8%)。作者认为免疫斑点法与CBA可比,可能作为实用选择。
要点
- 免疫斑点法检测AQP4-IgG与金标准CBA高度一致(κ=98.0%)。
- 总体灵敏度99.4%(95%CI 97.8%-99.9%),特异度99.2%(95%CI 98.0%-99.8%)。
- 验证集436例中仅2例(<1%)假阳性,无假阴性。
核心结论
- 免疫斑点法检测AQP4-IgG与CBA可比,具有省时省钱特点,可能作为AQP4-IgG检测的实用选择。
研究设计与样本
- 多中心病例对照研究,2020年5月至2023年2月,纳入4个医学中心(中国3个、韩国1个)。
- 共收集836份血清样本,其中400份纳入诊断研究,436份纳入验证集。
- 诊断研究纳入200例AQP4-IgG阳性NMOSD患者(平均[SD]年龄43.1[13.5]岁;188例[94%]女性)和200例健康对照。
主要发现
- 诊断研究中免疫斑点法与金标准CBA一致性κ=98.0%。
- 验证集436例中2例(<1%)假阳性,无假阴性。
- CBA识别332份AQP4-IgG阳性样本和504份阴性样本(对照200份[40%],其他疾病患者304份[60%]);阳性中2例(<1%)假阴性,阴性中4例(<1%)假阳性。
- 免疫斑点法总体灵敏度99.4%(95%CI 97.8%-99.9%),特异度99.2%(95%CI 98.0%-99.8%)。
临床怎么用
- 作者认为免疫斑点法可能作为AQP4-IgG检测的实用选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immunoglobulin G autoantibodies for aquaporin 4 (AQP4-IgG) serve as diagnostic biomarkers for neuromyelitis optica spectrum disorder (NMOSD), and the most sensitive and specific laboratory tests for their detection are cell-based assays (CBAs). Nevertheless, the limited availability of special instruments limits the widespread use of CBAs in routine laboratories. OBJECTIVE: To validate an enzyme immunodot assay for simple and rapid detection of AQP4-IgG. DESIGN, SETTING, AND PARTICIPANTS: This multicenter case-control study, conducted from May 2020 to February 2023, involved 4 medical centers (3 in China and 1 in Korea). The study included patients with AQP4-IgG-positive NMOSD, patients with other immune-related diseases, and healthy control individuals. Participants were excluded if they did not agree to participate or if their serum sample had turbidity. EXPOSURES: Serum AQP4 antibodies measured with immunodot assay. MAIN OUTCOMES AND MEASURES: The main outcome was performance of the immunodot assay compared with the gold standard CBA for detecting AQP4-IgG. To examine generalizability, cross-validation in Korea and at a second site in China, validation of patients with other immune-related diseases, and follow-up validation of the original cohort were performed. RESULTS: A total of 836 serum samples were collected; 400 were included in the diagnostic study and 436 in the validation sets. In a head-to-head diagnostic study involving 200 patients with NMOSD with AQP4-IgG (mean [SD] age, 43.1 [13.5] years; 188 [94%] female) and 200 healthy controls, use of an immunodot assay demonstrated antibody detection performance comparable to that of the gold standard (κ = 98.0%). The validation sets included 47 patients with NMOSD and 26 patients with other autoimmune diseases from Korea, 31 patients with NMOSD at a second site in China, 275 patients with other diseases, and 57 patients with NMOSD at follow-up. In the validation study, of 436 cases, 2 (<1%) were false positive and none were false negative. The CBA identified 332 AQP4-IgG-positive samples and 504 negative samples (200 [40%] in controls and 304 [60%] in patients with other diseases); 2 of the positive cases (<1%) were false negative and 4 of the negative cases (<1%) were false positive. The overall sensitivity of the immunodot assay was 99.4% (95% CI, 97.8%-99.9%), and the specificity was 99.2% (95% CI, 98.0%-99.8%). CONCLUSIONS AND RELEVANCE: This case-control study found that the immunodot assay was comparable to CBA for detecting AQP4-IgG. With its time- and cost-efficient characteristics, the immunodot assay may be a practical option for AQP4-IgG detection.
引用
- Fu Y, Bi J, Yan Y, et al. Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2023. PMID: 37669037. doi:10.1001/jamaneurol.2023.2974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。